Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

The Ohio State University

Status: Enrolling

Conditions: Breast Cancer

Treatments: Other: Specimen collection

Study type: Observational

Funder types: Other

Identifiers

NCT04022616

OSU-09142

Details and patient eligibility

About

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

Enrollment: 99 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older
• Ability to give informed consent
• Stage I-III breast malignancy

Exclusion criteria

• Unable to tolerate venipuncture

Trial design

99 participants in 4 patient groups

Immediate Surgery

Description:

Adult patients with breast malignancy.

Treatment:

Other: Specimen collection

Neo-adjuvant Chemotherapy

Description:

Adult patients with biopsy proven operable breast cancer who in the opinion of treating physician are suited to receive neo-adjuvant chemotherapy.

Treatment:

Other: Specimen collection

Lymph Node Tissue

Description:

Adult patients with breast malignancy who will be having a primary lymph node removed during breast surgery.

Treatment:

Other: Specimen collection

Metastatic Breast Cancer

Description:

Adult patients with biopsy proven stage IV breast cancer who are starting a new line palliative systemic therapy. A palliative systemic therapy will be defined in this trial as any chemotherapy regimen or combination of endocrine therapy with targeted agents such as cyclin dependent kinase 4/6 (CDK 4/6) inhibitors, HER2 targeting agents or inhibitors of mammalian target of rapamycin (mTOR).

Treatment:

Other: Specimen collection